AU2002224388A1 - Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules - Google Patents

Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules

Info

Publication number
AU2002224388A1
AU2002224388A1 AU2002224388A AU2438802A AU2002224388A1 AU 2002224388 A1 AU2002224388 A1 AU 2002224388A1 AU 2002224388 A AU2002224388 A AU 2002224388A AU 2438802 A AU2438802 A AU 2438802A AU 2002224388 A1 AU2002224388 A1 AU 2002224388A1
Authority
AU
Australia
Prior art keywords
lymphomas
methods
dendritic cells
treating cancers
tnf molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224388A
Inventor
Regis T. Costello
Yannis Morel
Daniel Olive
Raymond W. Sweet
Alemseged Truneh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002224388A1 publication Critical patent/AU2002224388A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002224388A 2000-10-18 2001-10-18 Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules Abandoned AU2002224388A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24142100P 2000-10-18 2000-10-18
US60/241,421 2000-10-18
PCT/US2001/032302 WO2002032463A1 (en) 2000-10-18 2001-10-18 Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules

Publications (1)

Publication Number Publication Date
AU2002224388A1 true AU2002224388A1 (en) 2002-04-29

Family

ID=22910622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224388A Abandoned AU2002224388A1 (en) 2000-10-18 2001-10-18 Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules

Country Status (2)

Country Link
AU (1) AU2002224388A1 (en)
WO (1) WO2002032463A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364653A4 (en) * 2001-02-23 2005-01-26 Takeda Pharmaceutical Casoase 3 inhibitors
US7811983B2 (en) 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
ES2297479T3 (en) 2003-06-11 2008-05-01 The University Of Chicago INFILTRATION INCREASED IN TUMOR OF CELLS T BY THE MUTANT LIGTH.
WO2011139629A2 (en) * 2010-04-26 2011-11-10 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140467A (en) * 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use

Also Published As

Publication number Publication date
WO2002032463A1 (en) 2002-04-25
WO2002032463A9 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
IL133311A0 (en) Imidazolyl-cyclic acetals
AU1803601A (en) Methods and compositions for the introduction of molecules into cells
AU2001239873A1 (en) Adjuvant treatment by in vivo activation of dendritic cells
WO2004080533A8 (en) Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue
WO2005046722A3 (en) Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
AU2001245852A1 (en) Stimulatory device and methods to electrically stimulate the phrenic nerve
EP1427445A4 (en) Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
AU2003293333A1 (en) Method of treating cancers
AU2002334749A1 (en) Methods and implantable apparatus for electrical therapy
AU1954001A (en) Methods for high level expression of genes in primates
AU7380500A (en) Methods for treating tumors using neutron therapy
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
AU6208100A (en) Cancer treatment using angiopoietins targeted to aminophospholipids
AU2003277044A1 (en) Method of treating cancer using adenosine and its analogs
AU2002224388A1 (en) Methods of treating cancers by stimulating dendritic cells or lymphomas with certain tnf molecules
AU5928599A (en) Methods for treating cell proliferative disorders including cancer
AU2003254196A8 (en) Methods for producing biological substances in pigment-deficient mutants of bacillus cells
AU7856100A (en) Methods for treating solid tumors with irradiation and bacteria
AU2002354957A1 (en) Biocompatible polymer containing composition for treatment of prostate cancers
AU2003213105A1 (en) Methods and compositions in treating pain using diacylglycerol kinase epsilon
AU1133901A (en) Method of treating metabolic disorders
AU2002224096A1 (en) Method of testing anticancer agent-sensitivity of tumor cells
AU2001241779A1 (en) Method of treatment of prostate cancer
AU2002219830A1 (en) Methods for treating disorders of neuronal deficiency with bone marrow-derived cells